Important note
This AI stock analysis for Bristol-Myers Squibb is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Bristol-Myers Squibb - AI Stock Analysis
Analysis generated July 21, 2024
Bristol Myers Squibb is a global biopharmaceutical company firmly rooted in a mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Headquartered in New York City, the company is well-established in the pharmaceutical industry with a diverse portfolio of products focusing on oncology, immunology, cardiovascular, and fibrotic diseases. The company operates globally and continues to be a major player in the pharmaceutical sector.
Fundamental Analysis
In evaluating Bristol Myers Squibb’s financial health, revenue for the last quarter stood at $11.9 billion. This reflects a 3.38% increase compared to the previous quarter, signaling a positive trend. Compared to the same quarter last year, there is a growth of 4.66%, indicating year-over-year growth. This is a positive indicator and suggests sustained demand for the company’s products.
However, the net income for the last quarter was also $11.9 billion, but it shows a drastic decrease of 775.99% compared to the quarter before it, and a decrease of 626.57% compared to the same quarter last year. Both substantial decreases signal significant concerns in operational efficiency or increased costs.
The EBITDA was recorded at $8.69 billion for the last quarter, marking a decrease of 302.66% compared to the previous quarter, and a decrease of 262.41% year-over-year. These steep drops indicate substantial changes in earnings before accounting for interest, taxes, depreciation, and amortization. Such a fall could suggest underlying operational difficulties.
The current P/E ratio is 12.66, which is within a typical range. This suggests that the stock is neither overvalued nor undervalued based on earnings.
Technical Analysis
Today’s stock price of Bristol Myers Squibb is $42.64, representing a 3.22% increase over the past month. This demonstrates a positive short-term trend. However, the stock price is down by 30.82% compared to a year ago – a cause for long-term concern.
The trend remains bullish, as indicated by the current SMA10 of 41.62, which is higher than the previous SMA10 of 41.43. This reflects a potential upward movement in the stock price. Additionally, the RSI is 22.6, indicating a potentially oversold but bullish condition. This could imply that the stock is trading at a lower price but has the potential for a rebound.
Alternative Data Analysis
Bristol Myers Squibb currently has 1,100 open positions as per data from popular job boards, up by 22% over the last few months, signaling a potential growth and expansion phase. This is typically a healthy sign for a company aiming to scale its operations.
However, the business outlook among employees is neutral, which suggests neither strong optimism nor pessimism internally. This can indicate potential internal uncertainties.
Customer acquisition appears concerning with an estimated 800,000 visitors to their webpage, a decrease of 10% over the past couple of months. Declining webpage visits can be an early indicator of waning customer interest or acquisition issues.
Customer engagement on social media platforms also presents a mixed picture. Bristol Myers Squibb maintains 21,000 Instagram followers with no significant change in recent months. On Twitter, the company has 160,000 followers, with a steady follower count, indicating stagnation in social media engagement.
Additionally, the AltIndex’s AI score that tries to predict the company’s stock price based on fundamental, technical, and alternative data analysis stands at 53, suggesting a hold signal.
Conclusion and Recommendation
In conclusion, Bristol Myers Squibb exhibits a somewhat mixed bag of indicators. Positive revenue growth is overshadowed by concerning declines in net income and EBITDA. The bullish technical indicators and potential upward price movement are counterbalanced by a significant drop in stock price over the past year.
Alternative data presents a cautious outlook with expanding job postings hinting at growth, yet a reduction in webpage visitors raises concerns. Stagnant social media engagement further clouds the customer engagement picture. The AI score of 53 (hold signal) amplifies the need for a balanced view.
Overall, while the stock shows some promise in the short term, the significant negative trends in fundamental data and mixed alternative data advise a cautious stance. Hence, based on the provided analysis, the recommendation is to hold the stock until more definitive positive trends emerge in their financial statements and customer engagement metrics.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
